Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.
Identifieur interne : 000B73 ( PubMed/Corpus ); précédent : 000B72; suivant : 000B74Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.
Auteurs : Sabeena Mustafa ; Hanan Balkhy ; Musa N. GabereSource :
- Journal of infection and public health [ 1876-035X ]
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antimicrobial Cationic Peptides, Antiviral Agents.
- therapy : Coronavirus Infections.
- Clinical Trials as Topic, Drug Repositioning, Humans.
Abstract
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. MERS-CoV infection has a high mortality rate, and to date, no therapeutic or vaccine has been discovered, that is effective in treating or preventing the disease. In this review, we summarize our understanding of the molecular and biological events of compounds acting as MERS-CoV inhibitors, the outcomes of existing therapeutic options and the various drugs undergoing clinical trials. Currently, several therapeutic options have been employed, such as convalescent plasma (CP), intravenous immunoglobulin (IVIG), monoclonal antibodies and repurposing of existing clinically approved drugs. However, these therapeutic options have drawbacks, thus the need for an alternative approach. The requirement for effective therapeutic treatment has brought the necessity for additional MERS treatments. We suggest that antimicrobial peptides (AMPs) may be used as alternative therapeutic agents against MERS-CoV infection. In addition, we propose the feasibility of developing effective agents by repurposing the existing and clinically approved anti-coronavirus and anti-viral peptide drugs.
DOI: 10.1016/j.jiph.2017.08.009
PubMed: 28864360
Links to Exploration step
pubmed:28864360Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.</title><author><name sortKey="Mustafa, Sabeena" sort="Mustafa, Sabeena" uniqKey="Mustafa S" first="Sabeena" last="Mustafa">Sabeena Mustafa</name><affiliation><nlm:affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Balkhy, Hanan" sort="Balkhy, Hanan" uniqKey="Balkhy H" first="Hanan" last="Balkhy">Hanan Balkhy</name><affiliation><nlm:affiliation>Infection Prevention and Control Department at the Ministry of National Guard, Department of Infectious Diseases, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Gabere, Musa N" sort="Gabere, Musa N" uniqKey="Gabere M" first="Musa N" last="Gabere">Musa N. Gabere</name><affiliation><nlm:affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia. Electronic address: mgabere@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2018 Jan - Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:28864360</idno><idno type="pmid">28864360</idno><idno type="doi">10.1016/j.jiph.2017.08.009</idno><idno type="wicri:Area/PubMed/Corpus">000B73</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.</title><author><name sortKey="Mustafa, Sabeena" sort="Mustafa, Sabeena" uniqKey="Mustafa S" first="Sabeena" last="Mustafa">Sabeena Mustafa</name><affiliation><nlm:affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Balkhy, Hanan" sort="Balkhy, Hanan" uniqKey="Balkhy H" first="Hanan" last="Balkhy">Hanan Balkhy</name><affiliation><nlm:affiliation>Infection Prevention and Control Department at the Ministry of National Guard, Department of Infectious Diseases, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Gabere, Musa N" sort="Gabere, Musa N" uniqKey="Gabere M" first="Musa N" last="Gabere">Musa N. Gabere</name><affiliation><nlm:affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia. Electronic address: mgabere@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of infection and public health</title><idno type="eISSN">1876-035X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimicrobial Cationic Peptides (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Coronavirus Infections (therapy)</term><term>Drug Repositioning</term><term>Humans</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimicrobial Cationic Peptides</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Drug Repositioning</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. MERS-CoV infection has a high mortality rate, and to date, no therapeutic or vaccine has been discovered, that is effective in treating or preventing the disease. In this review, we summarize our understanding of the molecular and biological events of compounds acting as MERS-CoV inhibitors, the outcomes of existing therapeutic options and the various drugs undergoing clinical trials. Currently, several therapeutic options have been employed, such as convalescent plasma (CP), intravenous immunoglobulin (IVIG), monoclonal antibodies and repurposing of existing clinically approved drugs. However, these therapeutic options have drawbacks, thus the need for an alternative approach. The requirement for effective therapeutic treatment has brought the necessity for additional MERS treatments. We suggest that antimicrobial peptides (AMPs) may be used as alternative therapeutic agents against MERS-CoV infection. In addition, we propose the feasibility of developing effective agents by repurposing the existing and clinically approved anti-coronavirus and anti-viral peptide drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28864360</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><MedlineDate>2018 Jan - Feb</MedlineDate></PubDate></JournalIssue><Title>Journal of infection and public health</Title><ISOAbbreviation>J Infect Public Health</ISOAbbreviation></Journal><ArticleTitle>Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.</ArticleTitle><Pagination><MedlinePgn>9-17</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-0341(17)30212-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2017.08.009</ELocationID><Abstract><AbstractText>Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. MERS-CoV infection has a high mortality rate, and to date, no therapeutic or vaccine has been discovered, that is effective in treating or preventing the disease. In this review, we summarize our understanding of the molecular and biological events of compounds acting as MERS-CoV inhibitors, the outcomes of existing therapeutic options and the various drugs undergoing clinical trials. Currently, several therapeutic options have been employed, such as convalescent plasma (CP), intravenous immunoglobulin (IVIG), monoclonal antibodies and repurposing of existing clinically approved drugs. However, these therapeutic options have drawbacks, thus the need for an alternative approach. The requirement for effective therapeutic treatment has brought the necessity for additional MERS treatments. We suggest that antimicrobial peptides (AMPs) may be used as alternative therapeutic agents against MERS-CoV infection. In addition, we propose the feasibility of developing effective agents by repurposing the existing and clinically approved anti-coronavirus and anti-viral peptide drugs.</AbstractText><CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Sabeena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balkhy</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Infection Prevention and Control Department at the Ministry of National Guard, Department of Infectious Diseases, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabere</LastName><ForeName>Musa N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 22490, Mail Code 1515, Riyadh 11426, Saudi Arabia. Electronic address: mgabere@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Public Health</MedlineTA><NlmUniqueID>101487384</NlmUniqueID><ISSNLinking>1876-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023181">Antimicrobial Cationic Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D023181" MajorTopicYN="N">Antimicrobial Cationic Peptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antimicrobial peptides</Keyword><Keyword MajorTopicYN="N">Convalescent plasma</Keyword><Keyword MajorTopicYN="N">Interferon</Keyword><Keyword MajorTopicYN="N">Intravenous immunoglobin</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">Peptide therapeutics</Keyword><Keyword MajorTopicYN="N">Ribavirin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28864360</ArticleId><ArticleId IdType="pii">S1876-0341(17)30212-5</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2017.08.009</ArticleId><ArticleId IdType="pmc">PMC7102797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2012 Jun;86(12):6434-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22491462</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Future Med Chem. 2012 Aug;4(12):1527-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22917241</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ther Deliv. 2013 Nov;4(11):1443-67</Citation><ArticleIdList><ArticleId IdType="pubmed">24228993</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4894-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24841268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2013 Dec;67(6):606-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24096239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 2014 Jan;42(Database issue):D1147-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24285301</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Pharm Des. 2007;13(2):143-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17269924</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2015 Feb;114:1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">25451075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2013;9(9):e1003595</Citation><ArticleIdList><ArticleId IdType="pubmed">24039577</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Immunol. 2009 Dec;158 Suppl 1:23-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19883421</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 2004 Jan 1;32(Database issue):D590-2</Citation><ArticleIdList><ArticleId IdType="pubmed">14681488</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2015 Jul;13(7):426-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26075364</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2017 Feb 14;91(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">28031370</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1995 Nov;69(11):7260-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7474149</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Dec;87(24):13134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24067982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2016 Feb 17;8(326):326ra21</Citation><ArticleIdList><ArticleId IdType="pubmed">26888429</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Virol. 2014 Oct;8:45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24997250</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2015 Jan;59(1):742-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25331705</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2015 Aug 7;290(32):19403-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26055715</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2014;5:3067</Citation><ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Sep 15;6:8223</Citation><ArticleIdList><ArticleId IdType="pubmed">26370782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2010 Oct 15;202(8):1171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20831383</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Parasitol. 2013 Mar;133(3):300-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23274811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation><ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 Mar 07;6:22677</Citation><ArticleIdList><ArticleId IdType="pubmed">26948040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26216974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 Aug 19;6:31629</Citation><ArticleIdList><ArticleId IdType="pubmed">27538452</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2014 Dec 19;194:200-10</Citation><ArticleIdList><ArticleId IdType="pubmed">25451066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2015 Jan;20(1):122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25450771</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2005 Apr 11;579(10):2130-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15811330</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2430</Citation><ArticleIdList><ArticleId IdType="pubmed">24069485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234ra59</Citation><ArticleIdList><ArticleId IdType="pubmed">24778414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation><ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2006 Jul;19(3):491-511</Citation><ArticleIdList><ArticleId IdType="pubmed">16847082</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Transl Med. 2015 Mar;3(3):35</Citation><ArticleIdList><ArticleId IdType="pubmed">25815296</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Immunol. 2005 Oct;142(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16178850</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Nov 28;503(7477):535-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24172901</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2015 Jul;36:54-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26072036</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Peptides. 2011 Jul;32(7):1518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21620914</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Springerplus. 2015 Nov 19;4:709</Citation><ArticleIdList><ArticleId IdType="pubmed">26618098</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2016 Mar 4;291(10):4894-902</Citation><ArticleIdList><ArticleId IdType="pubmed">26740631</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2016 Sep 12;90(19):8924-33</Citation><ArticleIdList><ArticleId IdType="pubmed">27466418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 2016 Jan 4;44(D1):D1087-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26602694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):231-5</Citation><ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation><ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2013 Aug;94(Pt 8):1749-1760</Citation><ArticleIdList><ArticleId IdType="pubmed">23620378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Chem Biol. 2013 Dec;9(12):761-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24231617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Epidemics. 2014 Dec;9:40-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25480133</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2011 Feb 22;8:76</Citation><ArticleIdList><ArticleId IdType="pubmed">21342525</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Chemother. 2015 Sep;47(3):212-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26483999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jun;87(12):6604-14</Citation><ArticleIdList><ArticleId IdType="pubmed">23552422</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(4):e34947</Citation><ArticleIdList><ArticleId IdType="pubmed">22536342</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2013 Sep;18(17-18):807-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23726889</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2013 Apr 30;4(3):e00165-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23631916</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2011 Feb 20;410(2):299-306</Citation><ArticleIdList><ArticleId IdType="pubmed">21176936</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1894-903</Citation><ArticleIdList><ArticleId IdType="pubmed">26164863</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">27095301</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2006 Sep;120(1-2):146-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16616792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2014 May 29;10(5):e1004166</Citation><ArticleIdList><ArticleId IdType="pubmed">24874215</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2011 Dec 16;11(1):37-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22173434</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Dec;87(23):12552-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24027332</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2015 Apr 2;201:61-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25733052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2016 Aug;14(8):523-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioinformatics. 2007 May 1;23(9):1148-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17341497</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2013;3:1686</Citation><ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2000 Dec;81(Pt 12):2867-2871</Citation><ArticleIdList><ArticleId IdType="pubmed">11086117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2016 Mar;490:49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">26828465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2012 Aug;167(2):322-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22659295</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2014 Sep 26;6(9):3683-98</Citation><ArticleIdList><ArticleId IdType="pubmed">25256397</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Oct;27(10):841-4</Citation><ArticleIdList><ArticleId IdType="pubmed">27132449</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood Transfus. 2016 Mar;14(2):152-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26674811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2012 Jun;94(3):288-96</Citation><ArticleIdList><ArticleId IdType="pubmed">22265858</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2015 Sep 5;386(9997):995-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">26049252</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25288733</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Top Pept Protein Res. 2012;13:93-110</Citation><ArticleIdList><ArticleId IdType="pubmed">26834391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2015;1282:1-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Mol Med. 2015 Aug 28;47:e181</Citation><ArticleIdList><ArticleId IdType="pubmed">26315600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2016;21(5):455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26492219</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Infect Dis. 2017 Feb 13;17(1):144</Citation><ArticleIdList><ArticleId IdType="pubmed">28193191</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2015;20(1):87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24831606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2003 Sep;3(9):710-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12949495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 Feb 25;6:22008</Citation><ArticleIdList><ArticleId IdType="pubmed">26911565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2017 Jan 15;228:7-13</Citation><ArticleIdList><ArticleId IdType="pubmed">27840112</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 2005;64:165-230</Citation><ArticleIdList><ArticleId IdType="pubmed">16139595</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2015 Aug 1;25(15):2923-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26048809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Pathol. 2000 Jun;53(3):111-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10897328</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2016 Aug;132:141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27312105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 May;87(10):5502-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23468491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000B73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28864360
|texte= Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28864360" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |